After reviewing the data, the DSMB will issue a report outlining their findings and recommendations. This report is sent to the study sponsor, who then communicates the necessary changes or updates to the clinical trial team. If the DSMB recommends significant changes or trial termination, these decisions are also communicated to regulatory authorities and ethics committees to ensure transparency and regulatory compliance.
